Mechanistically, PPARγ downregulates miR-21-5p by interacting with its promoter region, resulting in increased expression of SFRP5, an anti-inflammatory adipokine that regulates NASH progression [101]. The gene discussed is SFRP5; the disease is metabolic dysfunction-associated steatohepatitis.